Clinical Trials | February 25, 2026
Novo Nordisk unveils weight-loss data from REDEFINE 4 trial
CagriSema produced a 23% weight loss at 84 weeks, versus 25.5% for tirzepatide
CagriSema produced a 23% weight loss at 84 weeks, versus 25.5% for tirzepatide
The announcement follows a record-setting $1.2 million accelerated LineaDNA order
The Phase 2 trial, conducted through Starton’s Sargon Site Network, is expanding from two to six sites across the U.S.
This partnership represents a systemic shift from awareness to large-scale action for 57 lakh children
The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape
The collaboration merges biomodal’s 5-base and 6-base sequencing solutions, duet +modC and duet evoC
Nadda underlined that India’s policy framework is aligned with this transformation
Investment marks continued progress against AbbVie's $100 billion commitment to U.S. R&D and capital investments, including manufacturing, over the next decade
Prostate cancer is one of the fastest-growing cancers in India, with approximately 37,948 new cases each year
In 2025, over 1 million patients accessed Lilly treatments through LillyDirect
Subscribe To Our Newsletter & Stay Updated
